Nutriband Inc.
NTRBHealthcare|Biotechnology|US
$5.55
-0.03 (-0.45%)
Tangible Book / Share
$0.28
Cash / Share
$0.28
Financials
Financial Snapshot
Market Cap
$67.5M
Enterprise Value
$64.2M
Revenue (TTM)
$1.6M
Net Income (TTM)
-$7.0M
Cash & Investments
$3.4M
Net Cash
$3.2M
Free Cash Flow (TTM)
-$3.6M
Operating CF (TTM)
-$3.6M
Debt/Equity
0.04
Cash Runway & Burn Rate
Cash on Hand
$3.4M
Quarterly Burn
$908.1K
Monthly Burn
$302.7K
Est. Runway
~3.8 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $27.1K | $0.00 | $474.7K | $10.2K | $152.0K | $4.9M | $2.0M | $492.9K | $4.3M | $4.6M | $3.4M | |
| Operating Cash Flow | -$147.9K | -$92.9K | -$1.1M | -$894.5K | -$297.1K | -$2.8M | -$3.0M | -$3.5M | -$4.6M | -$5.1M | -$3.6M | |
| Free Cash Flow | -$147.9K | -$92.9K | -$1.1M | -$894.5K | -$297.1K | -$2.9M | -$3.1M | -$3.6M | -$4.7M | -$5.1M | -$3.6M | |
| Capital Expenditure | $0.00 | $0.00 | -$4.2K | $0.00 | $0.00 | -$81.6K | -$79.3K | -$51.8K | -$92.0K | -$5.3K | -$3.00 | |
| Financing Cash Flow | $174.9K | $65.8K | $2.0M | $430.3K | $371.9K | $7.6M | $160.1K | $2.1M | $8.5M | $5.4M | $58.9K |
R&D Spending
R&D (TTM)
$1.2M
R&D Intensity
75.1%
R&D Growth vs Prior
-35.8%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $245.3K | $370.6K | $943.7K | $1.4M | $2.1M | $2.1M | $2.1M | $2.0M | $1.6M | |
| R&D Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $411.4K | $982.2K | $2.0M | $3.1M | $1.9M | $1.2M | |
| R&D % of Revenue | — | — | 0.0% | 0.0% | 0.0% | 28.9% | 47.2% | 94.0% | 145.7% | 92.9% | 75.1% | |
| SG&A | $151.3K | $171.9K | $3.3M | $1.8M | $3.0M | $4.0M | $3.9M | $3.8M | $4.3M | $7.0M | $6.4M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $245.3K | $370.6K | $943.7K | $1.4M | $2.1M | $2.1M | $2.1M | $2.0M | $1.6M | |
| Cost of Revenue | $0.00 | $0.00 | $288.3K | $549.1K | $582.4K | $917.8K | $1.3M | $1.2M | $1.4M | $1.5M | $1.1M | |
| Gross Profit | $0.00 | $0.00 | -$43.0K | -$178.5K | $361.3K | $504.3K | $750.4K | $862.1K | $699.3K | $566.3K | $536.1K | |
| R&D | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $411.4K | $982.2K | $2.0M | $3.1M | $1.9M | $1.2M | |
| SG&A | $151.3K | $171.9K | $3.3M | $1.8M | $3.0M | $4.0M | $3.9M | $3.8M | $4.3M | $7.0M | $6.4M | |
| Operating Income | -$151.3K | -$171.9K | -$3.3M | -$2.0M | -$2.6M | -$3.9M | -$4.1M | -$4.9M | -$6.7M | -$8.3M | -$7.0M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $73.4K | $280.7K | $118.4K | $8.3K | $75.8K | $21.4K | $22.5K | $20.8K | |
| Pretax Income | -$151.3K | -$2.7M | -$3.3M | -$2.7M | -$2.9M | -$6.2M | -$4.5M | -$5.5M | -$10.5M | -$8.2M | -$7.0M | |
| Net Income | -$151.3K | -$2.7M | -$3.3M | -$2.8M | -$3.2M | -$8.4M | -$4.8M | -$5.5M | -$10.5M | -$8.2M | -$7.0M | |
| EPS (Diluted) | -0.03 | -0.48 | -0.53 | -0.44 | -0.48 | -1.06 | -0.57 | -0.69 | -0.99 | -2.58 | -0.57 | |
| EBITDA | $0.00 | -$2.5M | -$3.3M | -$2.6M | -$2.5M | -$5.7M | -$4.1M | -$5.1M | -$10.2M | -$8.0M | -$6.8M | |
| Shares Out. (M) | 6.06 | 5.60 | 6.24 | 6.33 | 6.73 | 7.93 | 8.46 | 7.95 | 10.61 | 11.64 | 12.16 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $27.1K | $0.00 | $474.7K | $10.2K | $152.0K | $4.9M | $2.0M | $492.9K | $4.3M | $4.6M | $3.4M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $37.7K | $164.9K | $590.5K | $43.2K | $314.2K | $5.5M | $2.7M | $1.0M | $4.8M | $5.0M | $3.8M | |
| Total Assets | $37.7K | $164.9K | $2.8M | $2.2M | $9.9M | $12.7M | $9.5M | $7.5M | $7.5M | $7.5M | $6.3M | |
| Total Current Liabilities | $14.6K | $43.4K | $403.0K | $2.0M | $2.6M | $779.3K | $748.6K | $999.1K | $982.8K | $784.3K | $907.0K | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $150.1K | $101.1K | $100.5K | $79.8K | $58.2K | $35.9K | $32.2K | |
| Total Liabilities | $14.6K | $43.4K | $403.0K | $2.0M | $2.8M | $880.4K | $883.4K | $1.1M | $1.0M | $868.4K | $964.4K | |
| Stockholders' Equity | $23.1K | $121.5K | $2.4M | $175.4K | $7.1M | $11.9M | $8.6M | $6.4M | $6.4M | $6.7M | $5.3M | |
| Retained Earnings | -$177.5K | -$2.8M | -$6.2M | -$8.9M | -$11.8M | -$18.0M | -$22.5M | -$28.0M | -$38.5M | -$46.7M | -$48.8M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$147.9K | -$92.9K | -$1.1M | -$894.5K | -$297.1K | -$2.8M | -$3.0M | -$3.5M | -$4.6M | -$5.1M | -$3.6M | |
| Capital Expenditure | $0.00 | $0.00 | -$4.2K | $0.00 | $0.00 | -$81.6K | -$79.3K | -$51.8K | -$92.0K | -$5.3K | -$3.00 | |
| Free Cash Flow | -$147.9K | -$92.9K | -$1.1M | -$894.5K | -$297.1K | -$2.9M | -$3.1M | -$3.6M | -$4.7M | -$5.1M | -$3.6M | |
| Investing Cash Flow | $0.00 | $92.9K | -$404.2K | $0.00 | $67.0K | -$81.6K | -$79.3K | -$51.8K | -$92.0K | -$5.3K | $0.00 | |
| Financing Cash Flow | $174.9K | $65.8K | $2.0M | $430.3K | $371.9K | $7.6M | $160.1K | $2.1M | $8.5M | $5.4M | $58.9K | |
| Issuance of Stock | $175.0K | $50.0K | $1.5M | $250.0K | $515.1K | $6.4M | $0.00 | $2.6M | $8.4M | $5.4M | $75.0K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$104.5K | -$119.0K | $0.00 | -$149.0K | $0.00 | -$1.1K | |
| Net Debt Issuance | $0.00 | $7.5K | $22.4K | $425.0K | -$161.5K | -$1.6M | -$17.8K | $2.1M | $8.7M | -$21.6K | -$15.0K | |
| Stock Based Comp. | $7.8K | $0.00 | $1.8M | $252.7K | $2.0M | $897.8K | $732.1K | $742.7K | $1.5M | $104.4K | $3.4M | |
| Net Change in Cash | $27.0K | $65.8K | $474.7K | -$464.5K | $141.8K | $4.7M | -$2.9M | -$1.5M | $3.8M | $263.1K | -$3.6M |
Dilution Tracker
Shares outstanding grew 72.9% over 5 years — significant dilution
Shares Outstanding
12M
5-Year Share Growth
+72.9%
Stock Issuance (TTM)
$75.0K
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 6.06 | 5.60 | 6.24 | 6.33 | 6.73 | 7.93 | 8.46 | 7.95 | 10.61 | 11.64 | 12.16 | |
| Change vs Prior % | — | -7.5% | 11.4% | 1.3% | 6.4% | 17.8% | 6.6% | -6.0% | 33.4% | 9.7% | 4.4% | |
| Stock Issuance | $175.0K | $50.0K | $1.5M | $250.0K | $515.1K | $6.4M | $0.00 | $2.6M | $8.4M | $5.4M | $75.0K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$104.5K | -$119.0K | $0.00 | -$149.0K | $0.00 | -$1.1K | |
| Stock Based Comp. | $7.8K | $0.00 | $1.8M | $252.7K | $2.0M | $897.8K | $732.1K | $742.7K | $1.5M | $104.4K | $3.4M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | -17.5% | -48.1% | 38.3% | 35.5% | 36.1% | 41.3% | 32.7% | 27.8% | 33.1% | |
| Operating Margin % | — | — | -1358.1% | -531.4% | -275.1% | -276.3% | -199.5% | -233.6% | -312.6% | -408.4% | -435.6% | |
| Net Margin % | — | — | -1358.1% | -754.1% | -340.5% | -592.2% | -231.3% | -263.0% | -489.9% | -404.1% | -430.4% | |
| EBITDA Margin % | — | — | -1343.0% | -689.8% | -263.1% | -403.6% | -197.5% | -245.6% | -475.5% | -393.5% | -421.0% | |
| FCF Margin % | — | — | -452.4% | -241.3% | -31.5% | -203.3% | -147.5% | -171.6% | -220.5% | -252.1% | -224.5% | |
| ROE % | -654.6% | -2199.0% | -138.5% | -1593.2% | -45.2% | -71.0% | -56.1% | -85.2% | -163.1% | -123.2% | -109.0% | |
| ROA % | -400.9% | -1620.4% | -118.7% | -127.2% | -32.4% | -66.1% | -50.9% | -73.0% | -140.3% | -109.0% | -110.6% | |
| ROIC % | -450.5% | -112.7% | -136.3% | -396.2% | -29.2% | -32.8% | -47.4% | -72.9% | -101.1% | -120.1% | -127.0% | |
| R&D / Revenue % | — | — | 0.0% | 0.0% | 0.0% | 28.9% | 47.2% | 94.0% | 145.7% | 92.9% | 75.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 51.1% | 154.6% | 50.7% | 46.2% | 0.3% | 2.6% | -4.8% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | -314.9% | 302.5% | 39.6% | 48.8% | 14.9% | -18.9% | -19.0% | |
| Operating Income | -37715.0% | -13.7% | -1837.4% | 40.9% | -31.8% | -51.4% | -5.5% | -17.5% | -37.3% | -24.3% | |
| Net Income | -37715.0% | -1666.5% | -24.7% | 16.1% | -15.0% | -162.1% | 42.9% | -14.0% | -91.1% | 21.5% | |
| EPS (Diluted) | -24900.0% | -1820.0% | -10.4% | 17.0% | -9.1% | -120.8% | 46.2% | -21.1% | -43.5% | -160.6% | |
| Operating Cash Flow | 0.0% | 37.2% | -1090.5% | 19.1% | 66.8% | -845.7% | -6.3% | -18.1% | -31.2% | -11.0% | |
| Free Cash Flow | 0.0% | 37.2% | -1095.0% | 19.4% | 66.8% | -873.2% | -6.1% | -16.7% | -31.8% | -8.8% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 138.8% | 99.6% | 59.1% | -39.4% | |
| SG&A Expense | 37715.0% | 13.7% | 1812.4% | -45.5% | 65.1% | 36.0% | -2.7% | -3.6% | 13.2% | 63.8% | |
| Total Assets | 11332.4% | 337.1% | 1602.6% | -21.7% | 351.7% | 28.3% | -25.8% | -20.5% | -0.6% | 1.0% | |
| Book Value / Share | 301.5% | 468.4% | 1675.9% | -92.8% | 3710.2% | 41.5% | -32.2% | -20.1% | -25.1% | -5.3% | |
| Debt | -1.2% | 196.6% | 28.8% | 704.0% | 455.9% | -92.5% | 38.1% | 29.9% | -22.8% | 31.7% | |
| Diluted Shares | 0.0% | -7.5% | 11.4% | 1.3% | 6.4% | 17.8% | 6.6% | -6.0% | 33.4% | 9.7% |
Valuation
P/E (TTM)At Loss
P/S41.70
10Y Low / Med / High9.96 / 40.95 / 146.13
P/B12.66
10Y Low / Med / High2.51 / 13.68 / 1504.50
EV/EBITDAAt Loss
EV/Revenue39.71
10Y Low / Med / High9.83 / 39.16 / 144.35
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$0.28
Net Current Assets / Share
$0.23
Graham Net-Net
$0.21
Cash / Share
$0.28
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -229.60 | -11.96 | -10.83 | -13.05 | -11.96 | -3.54 | -6.40 | -3.78 | -8.37 | -1.86 | -9.70 | |
| P/S Ratio | 0.00 | 0.00 | 146.13 | 98.00 | 40.95 | 20.92 | 14.85 | 9.96 | 41.09 | 27.38 | 41.70 | |
| P/B Ratio | 1504.50 | 264.71 | 14.91 | 207.04 | 5.43 | 2.51 | 3.60 | 3.22 | 13.68 | 8.35 | 12.66 | |
| EV/EBITDA | 0.00 | -12.75 | -10.75 | -14.33 | -16.23 | -4.35 | -7.08 | -4.00 | -8.24 | -6.42 | -9.43 | |
| EV/Revenue | 0.00 | 0.00 | 144.35 | 98.84 | 42.69 | 17.57 | 13.98 | 9.83 | 39.16 | 25.25 | 39.71 |
Analyst Estimates & Quality
Altman Z-Score
28.28
Safe
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 |
|---|---|---|
| Revenue | $95.4M | $180.4M |
| Net Income | $18.3M | $42.6M |
| EPS | $1.57 | $3.66 |
| # Analysts (EPS) | 1 | 1 |
Revenue Segments
By Geography
| Segment | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Non-US | $125.0K | $583.3K | — | — | — | $7.6K |
| UNITED STATES | $245.7K | — | $2.1M | $2.1M | $2.1M | $2.0M |